Topic summary
Type 2 diabetes and the largest part of the evidence base
This is a generated summary. It shows the 9 most-liked posts from a topic of 90, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
quiet_lurker, post #6: Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence. I am aware this is the third time this month I have made this point. Go to post
Speaking only to type 2 diabetes as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Coming back to post #35, because the follow-up matters more than the original answer.
Where two conditions pull in opposite directions, that is a clinical judgement rather than a lookup, and it is the kind of question a forum answers worst.
I have said this before in a thread nobody could find, so it is worth repeating.
25 likes 4mo
hana.sato, post #12: Picking up post #9: that is the part I would want checked first. On type 2 diabetes: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one. Go to post
Narrowing post #44, because the general version has more than one answer.
Post-authorisation safety studies are the place where under-studied populations eventually appear, and they are public.
The variance between people here is larger than the effect being discussed.
l.salinas, post #9: Narrowing post #8, because the general version has more than one answer. Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not independent variables. Go to post
Agreed on all of that, and I have nothing to add to it.
Answering the type 2 diabetes question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
33 likes 3mo
Read the full topic (90 posts)
This topic was referenced in
- Heart failure with preserved ejection fraction: symptom endpointsClinical › Comorbidities · 23 replies
- Type 2 diabetes and the largest part of the evidence base — does this still hold?Clinical › Comorbidities · 22 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Gallbladder disease risk with rapid weight loss
Revisiting: Gallbladder disease risk with rapid weight loss Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…
|
2 | 2k | 9mo | |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Reading back through what has been written here about cardiovascular…
|
4 | 12k | 5mo | |
|
Chronic kidney disease and the FLOW result
Posting this under the heading it deserves: Chronic kidney disease and the FLOW result Everything below is what sits behind that. Chronic kidney disease: setting out the arithmetic in full, because I have had…
|
+34 | 38 | 33k | 23mo |
|
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. PCOS and metabolic overlap, from the point of view of someone who has read the…
|
3 | 6.6k | 1d | |
|
Gallbladder disease risk with rapid weight loss
Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. Gallbladder disease risk — I have the observation and I do not trust my…
|
+56 | 63 | 34k | 18mo |
Related topics — sharing the tags chronic kidney disease, obstructive sleep apnoea, type 2 diabetes
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of adolescents is wrong? I ask because I have been…
|
3 | 11k | 9h | |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since
Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Putting the numbers in the first…
|
+125 | 132 | 39k | 16mo |
|
What SELECT changed about how semaglutide is discussed, and what it did not
Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not I was wrong about SELECT in a thread last spring and I would like to…
|
+120 | 132 | 2k | 14mo |
|
[2026 update] People with a low starting BMI: where the evidence stops
People with a low starting BMI: where the evidence stops Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
+19 | 23 | 62k | 23mo |